HC Wainwright & Co. assumes coverage of Odyssey Therapeutics at Buy, sets price target at $40
HC Wainwright & Co. initiated coverage of Odyssey Therapeutics with a Buy rating and a $40 price target, implying 111.9% upside from the Nov 5 close of $18.88.


